Adolescentes

Fewer teens are using cigarettes, alcohol, and most illicit drugs, according to NIDA’s latest Monitoring the Future study. Troubling  trends persist in marijuana use, however, and nonmedical prescription drug use remains a concern.

Teens who participated in the intervention Strong African American Families‒Teen at age 16 reported fewer conduct problems and depressive symptoms and less substance abuse at age 17‒18, compared to peers exposed to a control intervention.

NIDA-funded researchers have gathered evidence that brief interventions can help adolescents move away from drug use. In a clinical trial, middle and high school students markedly reduced their substance use following two 60-minute sessions that combined motivational interviewing and cognitive behavioral therapy.

NIDA Program Officer Dr. David Thomas speaks about the intertwined problems of pain and prescription opioid abuse, as well as the research supported by NIDA and the National Institutes of Health to address these problems.

Rates of adolescent cigarette smoking and alcohol drinking stood at historic lows in 2011, but marijuana use trended upward, according to the Monitoring the Future (MTF) survey.

Towns that implemented a drug abuse prevention program called Communities That Care will see a return of $5.30 for each $1 they invested during the 5-year trial of the intervention, according to a cost-benefit analysis. The estimate is based on reductions in smoking and delinquency observed during the fourth year of the study among eighth-graders and the projected total costs of smoking, delinquency, and crime avoided over the lifetimes of study participants.

Illicit drug use in the United States in 2010 was at its highest level since 2002, according to the most recent report from the National Survey on Drug Use and Health. A rise in marijuana use drove the increase. A favorable trend of falling cocaine use continued.

Adolescent, but not adult, drivers are more likely to take risks when peers are watching, a new study suggests.

New research suggests that differences in tobacco consumption reflect, in part, differences in the functional efficacy of a specific type of receptor in a pathway of the brain. In animal studies, nicotinic acetylcholine receptors with the α5 subunit played a key role in producing aversive responses to nicotine, thereby dissuading further consumption of the drug.